Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Sunil Verma, MD, MSEd, FRCPC
Advertisement
Articles by Sunil Verma, MD, MSEd, FRCPC
Advertisement
Latest Updated Articles
Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast CancerPublished: July 20th 2015 | Updated:
Advertisement
Advertisement
